Recent Publications

Tarr AJ, Powell ND, Reader BF, Bhave NS, Roloson AL, Carson WE 3rd, Sheridan JF. β-Adrenergic receptor mediated increases in activation and function of natural killer cells following repeated social disruption. Brain Behav Immun. 2012 Jul 14.

Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Choudhary MM, Kumar B, Teknos TN,Carson WE 3rd. Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery. 2012 Sep;152(3):431-40.

Luedke E, Jaime-Ramirez AC, Bhave N, Carson WE 3rd. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation. J Immunother. 2012 Jun;35(5):367-73.

Abdel-Rahman MH, Cebulla CM, Verma V, Christopher BN, Carson WE 3rd, Olencki T, Davidorf FH. Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival. Exp Eye Res. 2012 Jul;100:26-31.

Varker KA, Ansel A, Aukerman G, Carson WE 3rd. Review of complementary and alternative medicine and selected nutraceuticals: background for a pilot study on nutrigenomic intervention in patients with advanced cancer. Altern Ther Health Med. 2012 Mar-Apr;18(2):26-34. Review.

Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS Jr, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM; National Comprehensive Cancer Network. Melanoma. J Natl Compr Canc Netw. 2012 Mar;10(3):366-400.

Terando AM, Carson WE 3rd. Individualized local treatment strategies for in-transit melanoma. Oncology (Williston Park). 2011 Dec;25(14):1355, 1360.

Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE 3rd, O'Day SJ. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012 Jan 1;30(1):34-41.

Fagundes CP, Bennett JM, Alfano CM, Glaser R, Povoski SP, Lipari AM, Agnese DM, Yee LD, Carson WE 3rd, Farrar WB, Malarkey WB, Chen M, Kiecolt-Glaser JK. Social support and socioeconomic status interact to predict Epstein-Barr virus latency in women awaiting diagnosis or newly diagnosed with breast cancer. Health Psychol. 2012 Jan;31(1):11-9.

Fagundes CP, Glaser R, Alfano CM, Bennett JM, Povoski SP, Lipari AM, Agnese DM, Yee LD, Carson WE 3rd, Farrar WB, Malarkey WB, Kiecolt-Glaser JK. Fatigue and herpesvirus latency in women newly diagnosed with breast cancer. Brain Behav Immun. 2012 Mar;26(3):394-400.

Grignol V, Fairchild ET, Zimmerer JM, Lesinski GB, Walker MJ, Magro CM, Kacher JE, Karpa VI, Clark J, Nuovo G, Lehman A, Volinia S, Agnese DM, Croce CM, Carson WE 3rd. miR-21 and miR-155 are associated with Mitotic activity and Lesion Depth of Borderline Melanocytic Lesions. Br J Cancer. 2011 Sep 27;105(7):1023-9.

Grignol VP, Olencki T, Relekar K, Taylor C, Kibler A, Kefauver C, Wei L, Walker MJ, Chen HX, Kendra K, Carson WE 3rd. A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma. J Immunother. 2011 Jul-Aug;34(6):509-15.

Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula SV, Ray Chaudhury A, La Perle KM, Kreiner M, Young GS, Guttridge DC, Carson WE 3rd. MDSC inhibition of the IFN response in tumor-bearing mice. Cancer Res. 2011 Jun 16.

Mundy-Bosse BL, Young GS, Bauer T, Binkley E, Bloomston M, Bill MA, Bekaii-Saab T, Carson WE 3rd, Lesinski GB. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4(+) T cells from patients with GI malignancy. Cancer Immunol Immunother. 2011 May 21.

Guenterberg KD, Lesinski GB, Mundy-Bosse BL, Karpa VI, Jaime-Ramirez AC, Wei L, Carson WE 3rd. Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4(+) and CD8 (+) T cells. Cancer Immunol Immunother. 2011 May 21.

He H, Grignol V, Karpa V, Yen C, Laperle K, Zhang X, Jones NB, Liang MI, Lesinski GB, Ho WS, Carson WE 3rd, Lee LJ. Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment. J Control Release. 2011 May 10;151(3):239-45.

Mundy-Bosse BL, Thornton LM, Yang HC, Andersen BL, Carson WE. Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cell Immunol. 2011 Apr 23.

Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, Parihar R, Karpa V, Papenfuss TL, LaPerle KM, Biller E, Lehman A, Chaudhury AR, Jarjoura D, Burry RW, Carson WE 3rd. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J Immunol. 2011 Mar 15;186(6):3401-9.

He H, Grignol V, Karpa V, Yen C, Laperle K, Zhang X, Jones NB, Liang MI, Lesinski GB, Ho WS, Carson WE 3rd, Lee LJ. Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment. J Control Release. 2011 Feb 26.

Carson WE 3rd. Braking bad: blockage if inhibitory pathways improves interleukin-15 therapy.Clin Cancer Res. 2010 Dec 15;16(24):5917-9.

Bill MA, Fuchs JR, Li C, Yui J, Bakan C, Benson DM Jr, Schwartz EB, Abdelhamid D, Lin J, Hoyt DG, Fossey SL, Young GS, Carson WE, Li PK, Lesinski GB.  The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.  Mol Cancer. 2010 Jun 25;9:165.

Andersen BL, Thornton LM, Shapiro CL, Farrar WB, Mundy BL, Yang HC, Carson WE  Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants.  Clin Cancer Res. 2010 Jun 15;16(12):3270-8.

Li H, Lu Y, Piao L, Wu J, Yang X, Kondadasula SV, Carson WE, Lee RJ. Folate-immunoglobulin G as an anticancer therapeutic antibody. Bioconjug Chem. 2010 May 19;21(5):961-8.

Guenterberg KD, Grignol VP, Relekar KV, Varker KA, Chen HX, Kendra KL, Olencki TE, Carson WE 3rd. A Pilot Study of Bevacizumab and Interferon-alpha2b in Ocular Melanoma. Am J Clin Oncol. 2010 May 7.

Lesinski GB, Zimmerer JM, Kreiner M, Trefry J, Bill MA, Young GS, Becknell B, Carson WE 3rd. Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer. 2010 Apr 14;10:142.

Butchar JP, Mehta P, Justiniano SE, Guenterberg KD, Kondadasula SV, Mo X, Chemudupati M, Kanneganti TD, Amer A, Muthusamy N, Jarjoura D, Marsh CB, Carson WE 3rd, Byrd JC, Tridandapani S. Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy. Clin Cancer Res. 2010 Apr 1;16(7):2065-75.

Guenterberg KD, Grignol VP, Raig ET, Zimmerer JM, Chan AN, Blaskovits FM, Young GS, Nuovo GJ, Mundy BL, Lesinski GB, Carson WE. Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. Mol Cancer Ther. 2010 Feb;9(2):510-20.

Bhave NS, Carson WE. Immune modulation with interleukin-21. Ann N Y Acad Sci. 2009 Dec;1182:39-46.

Lesinski GB, Benninger K, Kreiner M, Quimper M, Young G, Carson WE. Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells. Cancer Immunol Immunother. 2009 Dec;58(12):2031-7.

Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, Lamb TA, Grever MR, Shapiro CL, Carson WE. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther. 2009 Nov;8(11):2983-91.

Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, Chalupa D, Otterson GA, Shapiro CL, Fowler JM, Grever MR, Bekaii-Saab TS, Carson WE. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol. 2009 Nov 1;27(31):5270-7.

Thornton LM, Andersen BL, Schuler TA, Carson WE. A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: secondary analysis of a randomized controlled trial. Psychosom Med. 2009 Sep;71(7):715-24.

Mani A, Roda J, Young D, Caligiuri MA, Fleming GF, Kaufman P, Brufsky A, Ottman S, Carson WE, Shapiro CL. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL 2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat. 2009 Sep;117(1):83-9.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu